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Background/aim: The male sling operation and artificial urinary sphincter implantation are common methods for treating urinary
incontinence. However, there are some drawbacks to these methods such as infection, urethral erosion, pain, inefficiency, and the
technical difficulty of the operations. Here we describe a new device we have named the Turkish Continence Device (TCD) which has
advantages over these other methods. The aim of this study was perform experiments with the TCD prototype in vivo and ex vivo to
determine efficiency, convenience of implantation, and negative effects.
Materials and methods: We implanted the prototype device in male goats and sheep, compressing the posterior urethra, and then fixed
it by sutures on the lateral sides of the cavernosal bodies, bilaterally. Then we recorded urodynamic findings and performed urinary
imaging. Additionally we measured urethral closure pressure ex vivo.
Results: The balloon volume for efficient urethral closure pressure using the new device was under 1 mL. It compressed the urethra
towards the corpus cavernosum perfectly, because the wings of the prototype device are fixed near the tunica of the cavernosal bodies
on each side.
Conclusion: A smaller device with smaller arms/wings would be efficient for obtaining enough pressure on the urethra. Additionally,
the technique for implanting the device is very simple and would likely be learned quickly.
Key words: Male urinary incontinence, treatment, novel compression technique, experimental study, Turkish Continence Device

1. Introduction
With the increasing numbers of radical prostatectomies,
male urinary incontinence has become common.
Multicenter studies and prostate cancer databases show
that after radical prostatectomy 1% to 40% of patients
complain of persistent urinary incontinence [1–3]. This
large variation may be based on the influence of the
interviewing physician and the lack of standardized
description
of
postprostatectomy
incontinence.
Iatrogenic-induced sphincter incompetence is the
cause of postoperative stress incontinence in 95% of
cases [4]. Many devices and techniques for treatment of
urinary incontinence have been identified. But none are
completely efficient, as there are drawbacks involving each
of them such as infection, urethral erosion, serious pain,
inefficiency, and the technical difficulty of the operations.
The aim of this experimental study is to develop a novel
prototype device (TCD) for achieving urinary continence

by compressing the male urethra towards the corpus
cavernosum.
2. Materials and methods
We used 3 male goats and 3 male sheep for the study, and
each animal was approximately 12 months old. Before
the study elaborating the anatomy of the animals, we
performed a cadaveric dissection of the penis and urethra
of these species. After that we excised the urethra and
penis as a block. The proximal urethra was chosen for
modeling and measuring the urethral pressure produced
by the TCD. We studied urethral closure pressures on
the apparatus using the excised penis–urethra specimen
with the prototype device implanted on it. We created
the apparatus by placing a prototype device on the
proximal urethra by suturing to the lateral surfaces of
the tunica albuginea of the cavernosal bodies bilaterally
with two sutures on each side (Figure 1). The prototype
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Figure 1. Prototype of novel devices includes for a Foley catheter
(6F or 8F) which its balloon covered with prolene mesh. Two
prolene wings fixed by suturing on cavernosal body’s tunica
bilaterally.

of the novel device included a Foley catheter (6F or
8F) covered all around with Prolene mesh. To avoid
displacement of the Foley balloon on the urethra, the
mesh leaves were braided using Prolene stitches around
the Foley balloon. Two Prolene wings were left bilaterally
to fix the device through suturing on the tunica of the
cavernosal body (Figure 1). Then, we inflated the Foley
balloon with saline (0.3–1.5 mL) until it stretched. We
inserted a Nelaton catheter from the distal transection
of the urethra, and this catheter was connected to
a saline bag via a serum set to measure the urethral
pressure produced by the external compression of the
TCD (Figure 2). When maximal stretch of the balloon
is reached, fluid flowing from the saline bag is stopped.
Then we shrank the balloon gradually and measured
urethral closure pressure (UCP).
After the postmortem examination of the animals,
we implanted the novel prototype devices in live animals.
We operated on three male sheep and three male goats in
order to implant the TCD model. Before the operations
we administered xylazine hydrochloride (0.2 mg/kg)
intravenously for premedication followed by ketamine
(17.5 mg/kg) intravenously for general anesthesia.
Under general anesthesia, the perineal area was shaved
and cleaned at the decubitus position. After painting the
perineal region with Batticon, we made a vertical incision
on the posterior part of the penile structures. Then we
located and isolated the cavernosal and spongiosal bodies.
We made an incision in the corpus spongiosum which is
thin and very adherent to the urethra in sheep and goats.
After incising the posterior urethra, we indwelled a 6F
or 8F Nelaton catheter for filling cystometry. It was very
difficult to attach the catheter transurethrally in rams and
goats without administering a muscle relaxant.

Figure 2. Measuring urethral closure pressure at different
volumes of TCD’s balloon.

We implanted TCD prototypes on the posterior urethra
by fixing them to the tunica albuginea of the cavernosal
bodies on each lateral side in all animals. The opposite
side of the Foley catheter has two tips; one is for balloon
inflation/deflation, and the other is for urine drainage.
We cut the tab of the urine drainage channel to facilitate
passing the catheter along the inner scrotal wall and out
of an incision on the lateral scrotal wall. We proposed to
inflate/deflate the balloon from this tip in order to arrange
urethral pressure after the operation. After implanting the
device and removing the inflating/deflating channel tip of
the Foley catheter from the body, we finished the operation
by closing the urethrostomy and skin incisions.
We inflated the Foley balloon with 0.3–1.5 mL of saline
in order to stretch it very tightly. After closing the incisions,
all animals were clothed to check for wetting with urine.
We wondered whether the animals would urinate or not
and injected a diuretic (Furosemide 2 mg/kg) in order to
observe this more quickly.
On the 7th day, a ram and a goat underwent an
imaging study to evaluate the degree and effect of
urethral obstruction. We performed intravenous nephropyelography and retrograde urethrography.
We fed all the animals for 1 month and then sacrificed
them. We excised the posterior urethra, including the
implanted TCD prototype, for pathologic investigation.
3. Results
After inserting the Nelaton catheter into the urethra in
the prototype device complex (apparatus 1), we measured
UCP. We observed that a little balloon volume was
enough to obtain efficient urethral closure pressure. The
necessary balloon volume for efficient UCP is under 1
mL which shows that continence would be achieved in
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incontinent men using very small devices. We repeated this
measurement procedure on apparatus 2 and reported all
UCP values at different volumes of Foley balloon in Table 1.
We were able to perform an urodynamic study
intraoperatively on two rams and two goats. The findings of
these studies are reported in Table 2.
We determined that the TCD prototype did not cause
complete obstruction because the clothes on all of the
animals became wet.
We could not establish any pathology on the renal
and vesicourethral images. Then we checked a Foley
balloon and saw that it had shrunk. At least the half of
the saline that was injected into the balloon during the
operation had emptied. We reinjected saline mixed with a
radiopaque substance then performed urethrography and
saw the balloon impression on the urethra and the effects
of a partial urethral obstruction (Figure 3). We reinjected
the previous amount of saline (0,3-1,5 mL) into the Foley
balloon fırt each animals.
When we sacrificed the animals and checked the Foley
catheter balloons we saw that they had shrunk again.
Macroscopically, Prolene mesh was embedded in the tissues
surrounding the urethra. It was dissected and the urethral
wall was isolated. There were no findings of urethral
erosion or damage due to the Prolene mesh (Figure 4).
Microscopic examination confirmed these findings; there
were no microscopic pathologic changes in the urethra and
corpus spongiosum (Figure 5).

fifth generation model, was created in 1983 [6]. Recently,
new devices have been developed to eliminate some of the
disadvantages of the AUS 800.
In an effort to improve the efficacy of AUS and
continence, tandem cuffs have been used with idea that
increasing the resistance over a greater area may improve
continence. Brito et al. first described a successful tandem
cuff placement, achieving 95% success [7]. Using two cuffs
would lead to increased resistance to leakage without
increasing pressure on a single segment of the urethra.
However, a subsequent, longer follow-up demonstrated a
higher risk of complications when using tandem cuffs [8].
In patients with recurrent incontinence secondary
to erosion, subcuff urethral atrophy, inadequate urethral
coaptation, or, for patients undergoing revisions where
more proximal placement could not be achieved,
transcorporal cuff placement may improve continence [9].
In a prospective series of transcorporal AUS placements,
dry or socially continent rates were reported to be 76% at a
median follow-up of 20 months [10].
There is a concern that transcorporal cuff placement
affects erectile dysfunction. However, most patients already
have some degree of erectile dysfunction at baseline due to
prostate cancer treatment [10–12]. A small series reported
that the majority of patients maintain their erectile function
even after transcorporal cuff placement (5/6, 83%) [10].
Transcorporal cuff placement is the only described
method in which the corpus cavernosum serves a function
in incontinence treatment. In our study, we also used
the corpus cavernosum’s tunica albugnea for fixing the
TCD; however, our method did not include dissecting the
cavernosal body as in transcorporal cuff placement. For

4. Discussion
The first artificial urinary sphincter was introduced in 1973
to treat urinary incontinence [5]. The AUS 800, which is the

Table 1. Urethral closure pressures at different volumes in the baloon on apparatuses 1 and 2.
Saline volume in the
balloon (ml)

Apparatus 1 urethral closure
pressure (cmH2O)

Apparatus 2 urethral closure
pressure (cmH2O)

1.5 ml

160

145

1.2 ml

115

95

0.9 ml

88

65

0.6 ml

56

34

0.3 ml

28

16

0 ml

12

10

Table 2. Bladder pressures at different bladder volumes in 4 subjects.
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Goat 1

Goat 2

Ram 1

Ram 2

Detrusor pressure of full bladder (cm H2O)

40

30

60

30

Bladder capasity (ml)

480

420

250

40
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Figure 3. Urethrography that shows balloon impression on
urethra and effect of partial urethral obstruction (B: Bladder, BN:
Bladder neck, U: Urethra, B-TCD: Balloon of TCD).

this reason, this new method is less invasive and we expect
that it will not have any effect on erectile function.
The flow secure sphincter was manufactured with
a supplemental reservoir to relieve stress pressure
during intraabdominal pressure increase. During the
bladder filling phase at low pressure, the pressureregulating reservoir keeps the bulbous urethra closed.
When intraabdominal pressure rises, the stress relief
balloon ensures additional pressure to the cuff to secure
continence [13–15].
The ZSI 375 (Zephyr Surgical Implants, Geneva,
Switzerland) has been developed recently to facilitate
AUS implantation1. The ZSI 375 consists of one piece
and is made up of 2 parts connected by tubing. One of
these parts is an adjustable cuff formed to fit around the
urethra. The other part is a pressure-regulating tank and
pump that is placed in the scrotum [16,17].
Another improvement in the artificial urinary
sphincter area is a novel, remotely-controlled sphincter
[18]. It was developed using an AMS 800 to replace the
pump. The new electronic pump has been designed to
be as small as possible to facilitate implantation and
compatibility with the existing AMS 800 tubing, cuff,
and balloon. The device is completely wireless and, when
tested on a fresh pig’s bladder, continence was achieved.
A novel artificial urinary sphincter tested in a canine
model is the tape mechanical occlusive device (TMOD)
[19]. The TMOD is a one-piece device for urinary
incontinence that utilizes a spring loaded mechanism to
apply constructive circumferential pressure on the urethra.

Figure 4. Dissecting and separating of prolene mesh from
urethral wall shows that there were not any findings of urethral
erosion or damage.

Malaeb et al. tested the functionality and biocompatibility
of the device in canines and examined the sizing and
occlusive efficiency in human cadavers.
An animal model was also used to improve a new
electromechanical artificial urinary sphincter (emAUS)
[20]. The emAUS consists of two parts; a contractile
unit, including two or more urethral cuffs that apply
synchronized sequential compression to the urethra,
which is implanted intracorporeally, and an electronic
board which controls it extracorporeally. The fibers of
each contractile unit are composed of nitinol, a metal
alloy of nickel and titanium. When the artificial muscles
forming each contractile unit are relaxed, the urethra
opens. The animal study, which was performed on male
sheep, showed that the emAUS can provide continence.
This new, electronically controlled sequential alternating
compression mechanism can circumvent damage
to urethral vascularity at least up to 3 months after
implantation.
Fabio Vilar improved the periurethral constrictor
(PUC) device in 1996 [21]. The PUC is a one-piece, twopart device. It is comprised of a constrictor cuff linked to a
valve, which is elliptical in shape, by a 20 cm silicone tube.
The valve is placed in a space accessible by percutaneous
puncture, and the system works hydraulically through the
injection of sterile saline solution.
A limited number of studies with controversial
results have been published regarding use of PUC in
postprostatectomic urinary incontinence (PPUI). In
one study 30 patients with PPUI were treated with PUC
implantation. In 22 patients (73.3%), good continence
was achieved [22]. In another study performed by Introini

Zephyr Surgical Implants (2016). ZSI 375 Artificial Urinary Sphincter [online]. Website http://www.zsimplants.ch/en/products-en/incontinence/zsi375-en [accessed 15 September 2016].
1
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Figure 5. Microscopic examination confirmed that there were not any pathologic changes in urethra and corpus spongiosum (Ü:
Urethra, CS: Corpus Spongiosum, CC: Corpus Cavernosum) are normal on section at TCD implanted level. There are not any pathologic
changes due to TCD.

et al., 66 patients with urinary incontinence following
radical prostatectomy were treated by PUC implantation.
Continence was recovered completely in 49 cases (79%),
partially in 9 (15%) cases, and remained unchanged in 4
(6%). In 4 cases (6%) the device was removed because of
infection/periurethral erosion [23].
Lima et al. reported a study with a very high device
removal rate 41.7% [24]. The most frequent complication
was urethral erosion (15 patients, 26.78%). Other
complications were mechanical malfunctions in 5,
urethral stenosis in 3, urinary fistula in 2, infection in 2,
and persistent urinary tract infection in 1 case. The overall
success rate was 30.35%.
Male sling procedures are the most commonly used
methods for the treatment of urinary incontinence. Tapes
are available, and the sling mechanism is based on the
concept of passive external urethral compression. Various
sling systems have been described. The Argus system is an
adjustable sling including a silicone cushion, two silicone
columns, and silicone rings/washers. It allows for implant
adjustment and regulation of the desired tension. There
are two techniques for implantation; the retro-pubic
approach and the transobturator approach (Argus T).
Hübner reported a series of 101 male patients treated
with the Argus sling for SUI [25]. Of these patients, 22
(21.8%) were treated with RT for local recurrence of
prostate cancer. After Argus implantation, adjustment
was necessary in 39 cases (38.6%). The second adjustment
to the sling tension was made in 7 patients. The third
and fourth adjustments were made in 3 patients and 1
patient, respectively. The median follow up was 2.2 years
and 80/101 (79.2%), and patients were considered dry
with a pad test of 0–1 g. Sixteen patients (15.8%) had
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complications requiring device removal due to urethral
erosion or infection after a mean of 371 days (range: 20–
1260).
The other male sling type is the four-arm I-STOP
transobturator male sling (TOMS) (CL Medical), which is
a monofilament polypropylene device. The dimensions are
45 × 1.4 cm with a 2.8 cm central part that is placed over
the urethra. Grise et al. reported a multicenter prospective
study including 122 patients with PPUI (94.9% radical
prostatectomy) [26]. At 12 months, only 69 patients
were available and 60 (87%) of them had improvement
in the number of pads used daily; 41, 14, and 5 patients
reported 0, 1, and >1 pad daily (PPD), respectively. The
only complication described was wounding of the corpus
cavernosum (4% of the patients).
The AdVance transobturator male sling (AMS,
Minnetonka, MN, USA) is also a polypropylene
monofilament mesh placed retro-urethrally by passing
tapes bilaterally through the obturator fossa. The AdVance
male sling essentially realigns the anatomy of the urethral
sphincter complex towards the normal configuration.
Rehder et al. reported a multiinstitutional study with 156
patients treated with the AdVance male sling for SUI [27].
Patients were considered cured if no pad or 1 dry pad for
security were used and if there was a reduction in daily
pad usage of 50%. All other situations were considered
failure. After implantation of the AdVance sling, pad usage
was significantly decreased compared with baseline (P <
0.0001) at 1 and 3 years. In the 1st year, 76.9% of patients
were classified as cured or improved, and this improvement
was 75.7% at the 3rd year. In total 109 complications were
registered which were mostly Dindo grade 1 (90 patients).
The most common complication was mild perineal pain.

ODABAŞ et al. / Turk J Med Sci
One sling device was explanted because of symphysitis. The
transient urinary retention rate was 9%.
The adjustable transobturator hydraulic male system
(ATOMS, AMI, Vienna, Austria) shares some similarity
with our device (TCD). The ATOMS has two components;
the adjustable cushion with mesh tapes suspending it
using the transobturator approach and the implantable
titanium port for adjusting the tension of the cushion and
pressure on the urethra [28]. Honda et al. reported the first
results of ATOMS implantation [29]. The most common
indications for placement of this device were SUI after
RP (92/99 patients) and failure of previous continence
device implantation surgeries (34/99). The mean pad use
decreased from 7.1 to 1.3 pads daily (P < 0.001), and 63%
patients were classified dry (0 pad: <10 mL at 24 h pad test)
and 29% were improved (1–2 pads: 10–40 mL daily). The
overall success rate was 92%. The most frequently (68.7%)
reported complications were transient pain or numbness
referred to the perineum, scrotum, or thighs which required
use of nonopioid analgesics for three to four weeks. Wound
infection at the site of the titanium port (leading to complete
explantation of the device) occurred in 4/99 patients.
The TCD is not a real artificial urinary sphincter, and it
is different from sling materials and methods as well. In male
sling methods, the posterior bulbous urethra is hung by
passing the arms of the sling material through the obturator
foramen or retro-pubic space bilaterally. The TCD does not
require long arms/tapes for fixation. Short wings are enough
to affix it to the cavernosal tunica on both sides. Furthermore,
it will be adjustable in humans with the inflation–deflation
port placed under the scrotal skin. The pressure on the

urethra would be adjusted by changing balloon volume
via injector needle insertion in the inflation–deflation port
through the punctured scrotal skin.
In conclusion, the TCD is much smaller than other
devices because it does not require long arms or tapes. It
provides sufficient pressure for continence because it sitting
exactly on the urethra. We use the cavernosal fascia for
holding and fixing the TCD instead of passing the tapes along
retro-pubic or transobturator routes. Because the device is
small and uses the least invasive implantation technique,
we estimate complications such as pain, infection, or
urethral erosion will be minimal. Additionally, the surgical
procedure is simpler, the implantation learning curve may
be shorter, and peroperative complications (organ, vessel,
or nerve injury) may be lower than in all other continence
device operations.
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